Welcome to LookChem.com Sign In|Join Free

CAS

  • or

159178-03-7

Post Buying Request

159178-03-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

159178-03-7 Usage

General Description

2,6-Dichloro-4-isocyanatopyridine is a chemical compound with the molecular formula C6H2Cl2N2O. It is a highly reactive and toxic compound that is used in the production of various chemicals, including agricultural pesticides and pharmaceuticals. 2,6-DICHLORO-4-ISOCYANATOPYRIDINE is classified as a hazardous substance and can cause severe skin and eye irritation, as well as respiratory issues if inhaled. It is important to handle this chemical with extreme caution and use proper protective equipment when working with it.

Check Digit Verification of cas no

The CAS Registry Mumber 159178-03-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,1,7 and 8 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 159178-03:
(8*1)+(7*5)+(6*9)+(5*1)+(4*7)+(3*8)+(2*0)+(1*3)=157
157 % 10 = 7
So 159178-03-7 is a valid CAS Registry Number.
InChI:InChI=1/C6H2Cl2N2O/c7-5-1-4(9-3-11)2-6(8)10-5/h1-2H

159178-03-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,6-DICHLORO-4-ISOCYANATOPYRIDINE

1.2 Other means of identification

Product number -
Other names 2,6-DICHLORO-4-PYRIDYL ISOCYANATE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:159178-03-7 SDS

159178-03-7Relevant articles and documents

4-Aminopyridine derivatives with anticholinesterase and antiamnesic activity

Scipione, Luigi,De Vita, Daniela,Musella, Alessandra,Flammini, Lisa,Bertoni, Simona,Barocelli, Elisabetta

, p. 309 - 312 (2008)

Several carbamate derivatives of 4-aminopyridine were synthesized and their anticholinesterase activity was evaluated. Compound 4d showed the highest inhibitory effect blocking non-competitively acetylcholinesterase and competitively butyrylcholinesterase

Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists

Luo, Dongdong,Guo, Zhikun,Zhao, Xuecui,Wu, Lijuan,Liu, Xiaochun,Zhang, Yingzhi,Zhang, Yuhang,Deng, Zirong,Qu, Xianjun,Cui, Shuxiang,Wan, Shengbiao

, (2021/10/25)

Sphingosine-1-phosphate receptor 2 (S1PR2) has been identified as a brand-new GPCR target for designing antagonists to reverse 5-FU resistance. We herein report the structural optimization and structure-activity relationship of JTE-013 derivatives as S1PR2 antagonists. Compound 9d was the most potent S1PR2 antagonist (KD = 34.8 nM) among developed compounds. Here, compound 9d could significantly inhibit the expression of dihydropyrimidine dehydrogenase (DPD) to reverse 5-FU-resistance in HCT116DPD and SW620/5-FU cells. Further mechanism studies demonstrated that compound 9d not only inhibited S1PR2 but also affected the transcription of S1PR2. In addition, compound 9d also showed acceptable selectivity to normal cells (NCM460). Importantly, compound 9d with suitable pharmacokinetic properties could significantly reverse 5-FU-resistance in the HCT116DPD and SW620/5-FU xenograft models without obvious toxicity, in which the inhibition rates of 5-FU were increased from 23.97% to 65.29% and 27.23% to 60.81%, respectively. Further immunohistochemistry and western blotting analysis also demonstrated that compound 9d significantly decreases the expression of DPD in tumor and liver tissues. These results indicated that compound 9d is a promising lead compound to reverse 5-FU-resistance for colorectal cancer therapy.

Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer

Cui, Shuxiang,Guo, Zhikun,Han, Gaitian,Liu, Shuai,Liu, Xiaochun,Luo, Dongdong,Lv, Yan,Qu, Xianjun,Tian, Xiaochen,Wan, Shengbiao,Wang, Wenyu,Yang, Shuang,Zhang, Yuhang

, (2021/08/20)

5-Fluorouracil (5-FU) and its prodrugs are the essential clinical drugs for colorectal cancer (CRC) treatment. However, the drug resistance of 5-FU has caused high mortality of CRC patients. Thus, it is urgent to develop reversal agents of 5-FU resistance. Sphingosine-1-phosphate receptor 2 (S1PR2) was proved to be a potential target for reversing 5-FU resistance, but the activity of known S1PR2 antagonists JTE-013 were weak in 5-FU-resistant cell lines. To develop more potent S1PR2 antagonists to treat 5-FU-resistant cancer, a series of JTE-013 derivatives were designed and synthesized. The most promising compound 40 could markedly reverse the resistance in 5-FU-resistant HCT116 cells and 5-FU-resistant SW620 cells via inhibiting the expression of dihydropyrimidine dehydrogenase (DPD). The key was that compound 40 with improved pharmacokinetic properties significantly increased the inhibitory rate of 5-FU in the SW620/5-FU cells xenograft model with no observable toxicity by inhibiting the expression of DPD in tumor and liver tissues. Altogether, these results suggest that compound 40 may be a promising drug candidate to reverse 5-FU resistance in the treatment of CRC.

S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer

Zhang, Yu-Hang,Luo, Dong-Dong,Wan, Sheng-Biao,Qu, Xian-Jun

, (2020/02/29)

In this study, S1PR2 was reckoned as a brand-new GPCR target for designing inhibitors to reverse 5-FU resistance. Herein a series of pyrrolidine pyrazoles as the S1PR2 inhibitors were designed, synthesized and evaluated for their activities of anti-FU-resistance. Among them, the most promising compound JTE-013, exhibited excellent inhibition on DPD expression and potent anti-FU-resistance activity in various human cancer cell lines, along with the in vivo HCT116DPD cells xenograft model, in which the inhibition rate of 5-FU was greatly increased from 13.01percent–75.87percent. The underlying mechanism was uncovered that JTE-013 demonstrated an anti-FU-resistance activity by blocking S1PR2 internalization to the endoplasmic reticulum (ER), which inhibited the degradation of 5-FU into α-fluoro-β-alanine (FBAL) by downregulating tumoral DPD expression. Overall, JTE-013 could serve as the lead compound for the discovery of new anti-FU-resistance drugs. Significance: This study provides novel insights that S1PR2 inhibitors could sensitize 5-FU therapy in colorectal cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 159178-03-7